Butler National And 2 Other US Penny Stocks To Watch

As the U.S. stock market shows signs of recovery with indices like the Dow Jones Industrial Average and S&P 500 trading higher following a softer-than-expected Producer Price Index report, investors are exploring diverse opportunities across various sectors. Penny stocks, often associated with smaller or newer companies, represent an intriguing segment of the market that can offer growth potential at lower price points. Despite being considered a somewhat outdated term, these stocks continue to attract attention when they demonstrate strong financial fundamentals and balance sheet resilience.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.33	$1.87B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$100.69M	★★★★★★
BAB (OTCPK:BABB)	$0.87	$6.14M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.41	$10.57M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.3175	$12.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.37	$44.07M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.23	$24.12M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9234	$86.33M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.55	$377.99M	★★★★☆☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Butler National (OTCPK:BUKS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Butler National Corporation, with a market cap of $117.60 million, operates in the aerospace industry by designing, manufacturing, and servicing aerostructures and aircraft components across North America and internationally.

Operations: The company's revenue is derived from its Gaming segment ($38.71 million), Aircraft Avionics ($2.49 million), Aircraft Modifications ($27.77 million), and Special Mission Electronics ($13.81 million).

Market Cap: $117.6M

Butler National Corporation has demonstrated significant earnings growth, with a notable 79.4% increase over the past year, outpacing the Aerospace & Defense industry. The company's financial health is supported by a satisfactory net debt to equity ratio of 33.1%, and its interest payments are well covered by EBIT at 8.9 times coverage. Despite stable weekly volatility and high-quality earnings, recent board changes highlight an inexperienced board with an average tenure of only 0.9 years. The company has also completed a substantial share buyback program, repurchasing over 15% of shares since December 2016.

• Unlock comprehensive insights into our analysis of Butler National stock in this financial health report.
• Learn about Butler National's historical performance here.

Inhibitor Therapeutics (OTCPK:INTI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on developing and commercializing therapeutics for certain cancers and non-cancerous proliferation disorders in the United States, with a market cap of $11.55 million.

Operations: Inhibitor Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $11.55M

Inhibitor Therapeutics, Inc. remains a pre-revenue company with a market cap of US$11.55 million, focusing on pharmaceutical development. The firm reported increased net losses for the third quarter and nine months ending September 2024, reflecting its ongoing unprofitability. However, Inhibitor Therapeutics is debt-free and has sufficient short-term assets to cover both short and long-term liabilities. Its cash runway extends over 1.6 years if its free cash flow continues to grow at historical rates. Despite high volatility compared to most US stocks, recent improvements in weekly volatility suggest some stabilization in share price movements.

• Click to explore a detailed breakdown of our findings in Inhibitor Therapeutics' financial health report.
• Examine Inhibitor Therapeutics' past performance report to understand how it has performed in prior years.

Lifeloc Technologies (OTCPK:LCTC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lifeloc Technologies, Inc. specializes in the development, manufacture, and marketing of portable hand-held and fixed station breathalyzers along with related accessories for various sectors including law enforcement and consumer markets worldwide, with a market cap of $8.26 million.

Operations: Lifeloc Technologies generates revenue primarily from its Products segment, accounting for $8.78 million, and a smaller portion from Rentals at $0.03 million.

Market Cap: $8.26M

Lifeloc Technologies, Inc., with a market cap of US$8.26 million, has experienced increased net losses over the past five years at a rate of 24.9% annually, highlighting its ongoing unprofitability. Despite this, the company maintains a satisfactory net debt to equity ratio of 5.3%, and its short-term assets of $4.8 million exceed both short-term and long-term liabilities totaling $1.88 million combined. Recent financing through a $750,000 subordinated debenture aims to support general corporate purposes but adds interest obligations at an annual rate of 8.25%. Shareholders have faced dilution with shares outstanding increasing by 8.6% last year.

• Click here and access our complete financial health analysis report to understand the dynamics of Lifeloc Technologies.
• Understand Lifeloc Technologies' track record by examining our performance history report.

Next Steps

• Click this link to deep-dive into the 720 companies within our US Penny Stocks screener.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com